TY - JOUR
T1 - The european particle therapy network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation
AU - work package 1 of the taskforce ''European Particle Therapy Network” of ESTRO
AU - De Roeck, Laurien
AU - van der Weide, Hiske L
AU - Eekers, Daniëlle B P
AU - Kramer, Miranda C
AU - Alapetite, Claire
AU - Blomstrand, Malin
AU - Burnet, Neil G
AU - Calugaru, Valentin
AU - Coremans, Ida E M
AU - Di Perri, Dario
AU - Harrabi, Semi
AU - Iannalfi, Alberto
AU - Klaver, Yvonne L B
AU - Langendijk, Johannes A
AU - Romero, Alejandra Méndez
AU - Paulsen, Frank
AU - Roelofs, Erik
AU - de Ruysscher, Dirk
AU - Timmermann, Beate
AU - Vitek, Pavel
AU - Weber, Damien C
AU - Whitfield, Gillian A
AU - Nyström, Petra Witt
AU - Zindler, Jaap
AU - Troost, Esther G C
AU - Lambrecht, Maarten
N1 - Copyright © 2022 Elsevier B.V. All rights reserved.
PY - 2022/3
Y1 - 2022/3
N2 - PURPOSE: Treatment-related toxicity after irradiation of brain tumours has been underreported in the literature. Furthermore, there is considerable heterogeneity on how and when toxicity is evaluated. The aim of this European Particle Network (EPTN) collaborative project is to develop recommendations for uniform follow-up and toxicity scoring of adult brain tumour patients treated with radiotherapy.METHODS: A Delphi method-based consensus was reached among 24 international radiation-oncology experts in the field of neuro-oncology concerning the toxicity endpoints, evaluation methods and time points.RESULTS: In this paper, we present a basic framework for consistent toxicity scoring and follow-up, using multiple levels of recommendation. Level I includes all recommendations that are considered minimum of care, whereas level II and III are optional evaluations in the advanced clinical or research setting, respectively. Per outcome domain, the clinical endpoints and evaluation methods per level are listed. Where relevant the organ at risk threshold doses for recommended referral to specific organ specialists are defined.CONCLUSION: These consensus-based recommendations for follow-up will enable the collection of uniform toxicity data of brain tumour patients treated with radiotherapy. This will facilitate collaboration and further propel the research field of radiation-induced toxicities relevant for these patients. An online tool to implement this guideline in clinical practice is provided at www.cancerdata.org.
AB - PURPOSE: Treatment-related toxicity after irradiation of brain tumours has been underreported in the literature. Furthermore, there is considerable heterogeneity on how and when toxicity is evaluated. The aim of this European Particle Network (EPTN) collaborative project is to develop recommendations for uniform follow-up and toxicity scoring of adult brain tumour patients treated with radiotherapy.METHODS: A Delphi method-based consensus was reached among 24 international radiation-oncology experts in the field of neuro-oncology concerning the toxicity endpoints, evaluation methods and time points.RESULTS: In this paper, we present a basic framework for consistent toxicity scoring and follow-up, using multiple levels of recommendation. Level I includes all recommendations that are considered minimum of care, whereas level II and III are optional evaluations in the advanced clinical or research setting, respectively. Per outcome domain, the clinical endpoints and evaluation methods per level are listed. Where relevant the organ at risk threshold doses for recommended referral to specific organ specialists are defined.CONCLUSION: These consensus-based recommendations for follow-up will enable the collection of uniform toxicity data of brain tumour patients treated with radiotherapy. This will facilitate collaboration and further propel the research field of radiation-induced toxicities relevant for these patients. An online tool to implement this guideline in clinical practice is provided at www.cancerdata.org.
U2 - 10.1016/j.radonc.2022.01.018
DO - 10.1016/j.radonc.2022.01.018
M3 - Review article
C2 - 35093408
SN - 0167-8140
SP - 241
EP - 249
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -